237 related articles for article (PubMed ID: 28972044)
1. Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group.
Erbe AK; Wang W; Carmichael L; Kim K; Mendonça EA; Song Y; Hess D; Reville PK; London WB; Naranjo A; Hank JA; Diccianni MB; Reisfeld RA; Gillies SD; Matthay KK; Cohn SL; Hogarty MD; Maris JM; Park JR; Ozkaynak MF; Gilman AL; Yu AL; Sondel PM
Clin Cancer Res; 2018 Jan; 24(1):189-196. PubMed ID: 28972044
[No Abstract] [Full Text] [Related]
2. HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy.
Erbe AK; Wang W; Reville PK; Carmichael L; Kim K; Mendonca EA; Song Y; Hank JA; London WB; Naranjo A; Hong F; Hogarty MD; Maris JM; Park JR; Ozkaynak MF; Miller JS; Gilman AL; Kahl B; Yu AL; Sondel PM
Front Immunol; 2017; 8():675. PubMed ID: 28659916
[TBL] [Abstract][Full Text] [Related]
3. Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab.
Erbe AK; Wang W; Carmichael L; Hoefges A; Grzywacz B; Reville PK; Ranheim EA; Hank JA; Kim K; Seo S; Mendonca EA; Song Y; Kenkre VP; Hong F; Gascoyne RD; Paietta E; Horning SJ; Miller JS; Kahl B; Sondel PM
J Immunother Cancer; 2019 Mar; 7(1):70. PubMed ID: 30871628
[TBL] [Abstract][Full Text] [Related]
4. KIR/KIR-ligand genotypes and clinical outcomes following chemoimmunotherapy in patients with relapsed or refractory neuroblastoma: a report from the Children's Oncology Group.
Erbe AK; Diccianni MB; Mody R; Naranjo A; Zhang FF; Birstler J; Kim K; Feils AS; Hung JT; London WB; Shulkin BL; Mathew V; Parisi MT; Servaes S; Asgharzadeh S; Maris JM; Park J; Yu AL; Sondel PM; Bagatell R
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36822669
[TBL] [Abstract][Full Text] [Related]
5. Genotypes of NK cell KIR receptors, their ligands, and Fcγ receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy.
Delgado DC; Hank JA; Kolesar J; Lorentzen D; Gan J; Seo S; Kim K; Shusterman S; Gillies SD; Reisfeld RA; Yang R; Gadbaw B; DeSantes KB; London WB; Seeger RC; Maris JM; Sondel PM
Cancer Res; 2010 Dec; 70(23):9554-61. PubMed ID: 20935224
[TBL] [Abstract][Full Text] [Related]
6. Impact of "Killer Immunoglobulin-Like Receptor /Ligand" Genotypes on Outcome following Surgery among Patients with Colorectal Cancer: Activating KIRs Are Associated with Long-Term Disease Free Survival.
Beksac K; Beksac M; Dalva K; Karaagaoglu E; Tirnaksiz MB
PLoS One; 2015; 10(7):e0132526. PubMed ID: 26181663
[TBL] [Abstract][Full Text] [Related]
7. KIR and HLA genotypes are associated with disease progression and survival following autologous hematopoietic stem cell transplantation for high-risk neuroblastoma.
Venstrom JM; Zheng J; Noor N; Danis KE; Yeh AW; Cheung IY; Dupont B; O'Reilly RJ; Cheung NK; Hsu KC
Clin Cancer Res; 2009 Dec; 15(23):7330-4. PubMed ID: 19934297
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032.
Yu AL; Gilman AL; Ozkaynak MF; Naranjo A; Diccianni MB; Gan J; Hank JA; Batova A; London WB; Tenney SC; Smith M; Shulkin BL; Parisi M; Matthay KK; Cohn SL; Maris JM; Bagatell R; Park JR; Sondel PM
Clin Cancer Res; 2021 Apr; 27(8):2179-2189. PubMed ID: 33504555
[TBL] [Abstract][Full Text] [Related]
9. Associations between KIR/KIR-ligand genotypes and clinical outcome for patients with advanced solid tumors receiving BEMPEG plus nivolumab combination therapy in the PIVOT-02 trial.
Feils AS; Erbe AK; Birstler J; Kim K; Hoch U; Currie SL; Nguyen T; Yu D; Siefker-Radtke AO; Tannir N; Tolaney SM; Diab A; Sondel PM
Cancer Immunol Immunother; 2023 Jul; 72(7):2099-2111. PubMed ID: 36823323
[TBL] [Abstract][Full Text] [Related]
10. Increased frequencies of the killer immunoglobulin-like receptor genes KIR2DL2 and KIR2DS2 are associated with neuroblastoma.
Keating SE; Ní Chorcora C; Dring MM; Stallings RL; O'Meara A; Gardiner CM
Tissue Antigens; 2015 Sep; 86(3):172-7. PubMed ID: 26202659
[TBL] [Abstract][Full Text] [Related]
11. KIR3DL1 Allelic Polymorphism and HLA-B Epitopes Modulate Response to Anti-GD2 Monoclonal Antibody in Patients With Neuroblastoma.
Forlenza CJ; Boudreau JE; Zheng J; Le Luduec JB; Chamberlain E; Heller G; Cheung NK; Hsu KC
J Clin Oncol; 2016 Jul; 34(21):2443-51. PubMed ID: 27069083
[TBL] [Abstract][Full Text] [Related]
12. Immunomonitoring of Stage IV Relapsed Neuroblastoma Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation and Subsequent GD2 (ch14.18/CHO) Antibody Treatment.
Seitz CM; Flaadt T; Mezger M; Lang AM; Michaelis S; Katz M; Syring D; Joechner A; Rabsteyn A; Siebert N; Troschke-Meurer S; Zumpe M; Lode HN; Yang SF; Atar D; Mast AS; Scheuermann S; Heubach F; Handgretinger R; Lang P; Schlegel P
Front Immunol; 2021; 12():690467. PubMed ID: 34367149
[TBL] [Abstract][Full Text] [Related]
13. Dinutuximab for maintenance therapy in pediatric neuroblastoma.
McGinty L; Kolesar J
Am J Health Syst Pharm; 2017 Apr; 74(8):563-567. PubMed ID: 28389455
[TBL] [Abstract][Full Text] [Related]
14. Impact of killer-immunoglobulin-like receptor and human leukocyte antigen genotypes on the efficacy of immunotherapy in acute myeloid leukemia.
Bernson E; Hallner A; Sander FE; Wilsson O; Werlenius O; Rydström A; Kiffin R; Brune M; Foà R; Aurelius J; Martner A; Hellstrand K; Thorén FB
Leukemia; 2017 Dec; 31(12):2552-2559. PubMed ID: 28529313
[TBL] [Abstract][Full Text] [Related]
15. Killer immunoglobulin-like receptor (KIR) and KIR-ligand genotype do not correlate with clinical outcome of renal cell carcinoma patients receiving high-dose IL2.
Wang W; Erbe AK; Gallenberger M; Kim K; Carmichael L; Hess D; Mendonca EA; Song Y; Hank JA; Cheng SC; Signoretti S; Atkins M; Carlson A; Weiss JM; Mier J; Panka D; McDermott DF; Sondel PM
Cancer Immunol Immunother; 2016 Dec; 65(12):1523-1532. PubMed ID: 27695964
[TBL] [Abstract][Full Text] [Related]
16. Impact of incompatible killer cell immunoglobulin-like receptor and its ligand on the outcome of haploidentical bone marrow transplantation.
Duan LN; Han HX; Liu J; Yan HM; Zhu L; Xue M; Ding L; Zhu PY; Wang HX; Ji SQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Aug; 15(4):809-15. PubMed ID: 17708809
[TBL] [Abstract][Full Text] [Related]
17. KIR and HLA genotypes predictive of low-affinity interactions are associated with lower relapse in autologous hematopoietic cell transplantation for acute myeloid leukemia.
Marra J; Greene J; Hwang J; Du J; Damon L; Martin T; Venstrom JM
J Immunol; 2015 May; 194(9):4222-30. PubMed ID: 25810393
[TBL] [Abstract][Full Text] [Related]
18. Donor KIR3DL1/3DS1 gene and recipient Bw4 KIR ligand as prognostic markers for outcome in unrelated hematopoietic stem cell transplantation.
Gagne K; Busson M; Bignon JD; Balère-Appert ML; Loiseau P; Dormoy A; Dubois V; Perrier P; Jollet I; Bois M; Masson D; Moine A; Absi L; Blaise D; Charron D; Raffoux C;
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1366-75. PubMed ID: 19822295
[TBL] [Abstract][Full Text] [Related]
19. Dinutuximab: An Anti-GD2 Monoclonal Antibody for High-Risk Neuroblastoma.
Ploessl C; Pan A; Maples KT; Lowe DK
Ann Pharmacother; 2016 May; 50(5):416-22. PubMed ID: 26917818
[TBL] [Abstract][Full Text] [Related]
20. Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin.
Kushner BH; Ostrovnaya I; Cheung IY; Kuk D; Modak S; Kramer K; Roberts SS; Basu EM; Yataghene K; Cheung NK
Oncotarget; 2016 Jan; 7(4):4155-66. PubMed ID: 26623730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
